First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.

Published Date: 02 Feb 2024

Out of 35 evaluable patients, 16 showed responses to cabotezantinib-pembrolizumab; one patient was still required.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Medical Journal March 29, 2023

2.

Early breast cancer detection may be possible with a wearable ultrasound scanner.

3.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

4.

Standardized criteria for amino acid PET imaging could improve diagnosis and treatment of brain metastases

5.

Could CT scans be fueling a future rise in cancer cases, as a new study suggests?


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot